// App-Quantinova.ai

PB1049 : Lack of Inhibitor Development after Switching to Rurioctocog Alfa Pegol in the American Thrombosis and Hemostasis Network (ATHN) 2: Factor Switching Study

Researchers

Presenter

  • J. Journeycake

Principal Investigators

  • J. Caicedo

  • D. Cheng

  • M. Denne

  • C. Guelcher

  • S. Lattimore

  • M. Ragni

  • M. Recht

  • R. Sidonio

  • C. Takemoto

  • M. Tarantino

  • C. Watson

  • E. Neufeld

Medical Centers

  • University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

  • Baxalta US Inc., a Takeda Company, Cambridge, United States

  • American Thrombosis Hemostasis Network, Rochester, United States

  • 4Children’s National Washington DC United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • Universityof Pittsburgh and the Haemophilia Center of WesternPennsylvania, Pittsburgh, PA, United States

  • Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, United States

  • Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, United States

  • St Jude Childrens Research Hospital, Memphis, TN, United States

  • Bleeding and Clotting Disorders Institute, Peoria, IL, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Hemophilia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rurioctocog alfa

  • FVIII

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02546622

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved